Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Repozitorij Univerze v Ljubljani
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Napredno
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Podrobno
The role of focal adhesion kinase in bladder cancer : translation from in vitro to ex vivo human urothelial carcinomas
ID
Markovič, Gaja
(
Avtor
),
ID
Resnik, Nataša
(
Avtor
),
ID
Janev, Aleksandar
(
Avtor
),
ID
Zupančič, Daša
(
Avtor
),
ID
Grubelnik, Gašper
(
Avtor
),
ID
Debeljak, Maruša
(
Avtor
),
ID
Čemažar, Maja
(
Avtor
),
ID
Jesenko, Tanja
(
Avtor
),
ID
Omerzel, Maša
(
Avtor
),
ID
Smrkolj, Tomaž
(
Avtor
),
ID
Erdani-Kreft, Mateja
(
Avtor
)
URL - Izvorni URL, za dostop obiščite
https://reference-global.com/article/10.2478/raon-2025-0052
PDF - Predstavitvena datoteka,
prenos
(2,17 MB)
MD5: A5DE935112BCBAD422671A7C931BE3C9
Galerija slik
Izvleček
Background: Focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase, plays a crucial role in focal adhesion turnover by interfacing between the extracellular space, transmembrane integrins, and actin filaments. Its significance for the progression of several malignancies, including bladder cancer, has been well-documented. However, its precise role and the implications of its inhibition in bladder cancer tissues and urothelial in vitro models has not been fully explored. This study examined FAK expression and function in human bladder cancer biopsies and in vitro bladder cancer models. Materials and methods: Ex vivo analyses were performed using reverse transcription-quantitative PCR (qRT-PCR), western blotting, and immunohistochemistry to compare FAK expression between bladder cancer tissues and adjacent normal tissues. In vitro, FAK expression was assessed in low-grade (LG) human non-invasive papilloma urothelial cell line RT4 for NMIBC (Ta), high-grade (HG) human muscle-invasive cancer urothelial cell line T24 for MIBC (T2) and normal porcine urothelial (NPU) cells using qRT-PCR and western blotting, as well as flow cytometry for the quantification of FAK-positive RT4 and T24 cells. The role of FAK in cancer cell survival was explored in vitro using microRNA (miRNA) to silence FAK expression. Additionally, we used FAK inhibitors PND-1186, PF-573228 and defactinib to investigate the effects of FAK inhibition on normal compared to cancerous bladder urothelial cells. Results: Ex vivo analyses demonstrated significantly higher FAK expression in bladder cancer tissues compared to adjacent normal tissues. Similarly, in vitro analyses showed significantly higher FAK expression in RT4 and T24 cells than NPU cells. Silencing FAK using anti-FAK plasmids led to increased caspase-3-mediated apoptosis of RT4 and T24 cells and growth reduction of stably transfected T24 cells. Importantly, based on cell viability assays, treatment with 100 μM defactinib for 2 hours per day on 3 consecutive days was identified as a clinically relevant regimen. Under this treatment, the viability of differentiated NPU cells remained high at 108.4 ± 17.1%, while the viability of 2-day RT4 and 2-day T24 cells was drastically reduced to 4.1 ± 2.7% and 7.6 ± 2.9%, respectively. Conclusions: To our knowledge, this is the first report demonstrating the role of FAK and its inhibition across both normal and cancerous bladder urothelial models. This study highlights the critical role of FAK in the progression of human bladder cancer and establishes a foundation for exploring FAK inhibition as a potential therapeutic approach in bladder cancer treatment.
Jezik:
Angleški jezik
Ključne besede:
bladder cancer
,
defactinib
,
focal adhesion kinase
,
human urothelial carcinoma
,
urothelial cell
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Datum objave:
01.01.2025
Leto izida:
2025
Št. strani:
Str. 349-367
Številčenje:
Vol. 59, iss. 3
PID:
20.500.12556/RUL-176793
UDK:
616.6-006
ISSN pri članku:
1318-2099
DOI:
10.2478/raon-2025-0052
COBISS.SI-ID:
251661571
Datum objave v RUL:
16.12.2025
Število ogledov:
36
Število prenosov:
2
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Radiology and oncology
Skrajšan naslov:
Radiol. oncol.
Založnik:
Association of Radiology and Oncology
ISSN:
1318-2099
COBISS.SI-ID:
32649472
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
rak mehurja
,
defaktinib
,
fokalna dhezijska kinaza
,
humani urotelialni karcinom
,
urotelijska celica
Projekti
Financer:
ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:
P3-0108
Naslov:
Celična biologija in molekularna genetika v biomedicini
Financer:
ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:
P3-0003
Naslov:
Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev
Financer:
ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:
J7-2594
Naslov:
Uporaba amnijske membrane za inovativno multimodalno zdravljenje bakterijskega cistitisa in raka sečnega mehurja: učinek njene protimikrobne, imunomodulatorne in protirakave aktivnosti
Financer:
ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:
J3-2521
Naslov:
Vnetni proces pri intersticijskem cistitisu in ovrednotenje delovanja agonistov kanabinoidnih receptorjev sečnega mehurja – od celic do pacienta
Financer:
ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:
MRIC UL IP-0510
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj